Get started
Author

Kai He

Initial safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)–targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH).
2026 · Julian R. Molina, Jeffrey Ward, et al. · Journal of Clinical Oncology · 5
A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.
2026 · Salman Rafi Punekar, Sandip Pravin Patel, et al. · Journal of Clinical Oncology · 1
PDF
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
2026 · Byoung Chul Cho, Rama Balaraman, et al. · Nature Medicine · 1
PP01.26: Real-World Time Toxicity of Tarlatamab in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2026 · Jinesh Gheeya, Athanasios Papadas, et al. · Journal of Thoracic Oncology
PP01.55: Early Clinical Activity of GT201, a mbIL-15–Engineered Tumor Infiltrating Lymphocyte Therapy in Relapsed EGFR-Mutated Metastatic NSCLC
2026 · Shriya Deshmukh, Jing Yu, et al. · Journal of Thoracic Oncology
A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic EGFR -mutated non–small cell lung cancer (NSCLC).
2026 · Regan Michelle Memmott, Jinesh S. Gheeya, et al. · Journal of Clinical Oncology
XPC restrains cancer stemness by modulating STAT1-SOX2 signaling in non-small cell lung cancer
2026 · Qi-En Wang, Na Li, et al. · Research Square
PDF
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
2026 · Qing Zhou, Bo Gao, et al. · BMJ Oncology
PDF
Works count: 10
Citation count: 8
H-index: 1
I10-index:
Year
Topic
Type